Blosozumab
Blosozumab
Blosozumab (pronunciation: blo-so-zu-mab) is a monoclonal antibody designed for the treatment of osteoporosis. It functions by inhibiting the activity of sclerostin, a protein that inhibits bone formation.
Etymology
The name "Blosozumab" is derived from the combination of "bloso", a prefix used in the naming of monoclonal antibodies, and "zumab", a suffix used to denote humanized antibodies.
Mechanism of Action
Blosozumab works by binding to sclerostin, a protein that inhibits the activity of osteoblasts, the cells responsible for bone formation. By inhibiting sclerostin, blosozumab allows for increased bone formation and decreased bone resorption, leading to an overall increase in bone mass.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Osteoporosis: A condition in which the bones become weak and brittle.
- Sclerostin: A protein produced by osteocytes that inhibits bone formation.
- Osteoblast: A cell that secretes the matrix for bone formation.
See Also
External links
- Medical encyclopedia article on Blosozumab
- Wikipedia's article - Blosozumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski